Publications Archive - KalVista Pharmaceuticals

Patients & Caregivers
- About HAE
Healthcare Professionals
Clinical Trials
Presentations & Publications
Investors & News

About
Science
Pipeline
Careers
- Careers
- Job Openings
Contact

Presentations & Publications

We are committed to rigorous science and innovative drug development, and we are excited to share our ongoing progress.

Explore Our
Virtual Medical Booth

Filtered (2)

Filters

Reset all ×
2013 ×
2016 ×

Apply Reset

Topic

Sebetralstat (KVD900) in HAE clinical program (0)
HAE attack journey data (0)
HAE burden of treatment data (0)
Oral Factor XIIa inhibitor (0)

Forum

Medical Meeting (0)
Publication (2)

Year

2024 (23)
2023 (48)
2022 (22)
2021 (8)
2020 (0)
2019 (5)
2018 (3)
2017 (1)
2016 (1)
2015 (1)
2013 (1)
2011 (2)
2010 (1)
2009 (1)
2008 (1)
2007 (1)

Show (2)

Cancel

Apply Reset

Showing 2 out of 2

Plasma Kallikrein Mediates Vascular Endothelial Growth Factor-Induced Retinal Dysfunction and Thickening.

Clermont A, Murugesan N, Zhou Q, Kita T, Robson PA, Rushbrooke LJ, Evans DM, Aiello LP, and Feener EP.
Invest Ophthalmol Vis Sci. 2016; 57:2390-9.
PMID:27138737

Intraocular hemorrhage causes retinal vascular dysfunction via plasma kallikrein.

Liu J, Clermont AC, Gao BB, Feener EP.
Invest Ophthalmol Vis Sci. 2013;54:1086-1094.
PMID:23299478

About

Management team

Board of Directors

Science

Pipeline

Sebetralstat

Oral Factor XIIa Inhibitor

Careers

Job Openings

Contact

KalVista Terms of Use Privacy Policy